triple-negative breast cancer

GPTKB entity

Predicate	Object
gptkbp:instance_of	gptkb:healthcare_organization
gptkbp:bfsLayer	4
gptkbp:bfsParent	gptkb:Tecentriq
gptkbp:advocates_for	important for support important for awareness important for research funding
gptkbp:associated_with	BRC A1 mutations BRC A2 mutations
gptkbp:clinical_trial	ongoing studies combination therapies new drug therapies
gptkbp:end_of_life	varies by stage lower than hormone receptor-positive breast cancer
gptkbp:events	may include blood tests important for monitoring recurrence may include regular imaging
gptkbp:genetic_diversity	recommended for high-risk individuals
https://www.w3.org/2000/01/rdf-schema#label	triple-negative breast cancer
gptkbp:is_characterized_by	lack of HE R2 protein lack of estrogen receptors lack of progesterone receptors
gptkbp:is_involved_in	available for patients
gptkbp:is_often_used_in	African American women younger women
gptkbp:public_awareness	focused on education focused on early detection focused on research funding
gptkbp:research_focus	gptkb:vaccine targeted therapy
gptkbp:risk_factor	obesity exposure to radiation lack of physical activity family history of breast cancer
gptkbp:social_responsibility	biopsy imaging tests generally poorer than other types of breast cancer
gptkbp:symptoms	changes in breast shape lump in the breast nipple discharge
gptkbp:tour	Stage I Stage II Stage III Stage IV
gptkbp:treatment	gptkb:hospital radiation therapy chemotherapy